Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
teriparatide 20 micrograms/day · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | teriparatide 20 micrograms/day subcutaneous |
| B | ACTIVE_COMPARATOR | salmon calcitonin 100 IU/day subcutaneous |
| Name | Type | Description |
|---|---|---|
| teriparatide 20 micrograms/day subcutaneous | DRUG | - |
| salmon calcitonin 100 IU/day subcutaneous | DRUG | - |
| calcitonin 100 IU/day subcutaneous | DRUG | - |
Inclusion Criteria: * Ambulatory, postmenopausal women aged 55-85 years (at least 3 years have elapsed after menopausal) are included at the time of entry into the trial. They have to be free of severe or chronically disabling conditions other than osteoporosis. * The patient should have a document...
Teriparatide 20 micrograms/day is used for the treatment of osteoporosis in postmenopausal women. It is being developed by Eli Lilly and Company and is currently in Phase 3 clinical development. The drug is a small molecule administered at a dose of 20 micrograms per day.
Teriparatide 20 micrograms/day is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The drug is being studied for the treatment of postmenopausal osteoporosis and is currently in Phase 3 clinical trials.
Teriparatide 20 micrograms/day is in Phase 3 clinical development. It is an investigational drug for the treatment of osteoporosis in postmenopausal women. The clinical trials for this drug have been completed, and it is not yet approved by regulatory authorities.
Teriparatide 20 micrograms/day has been studied in three Phase 3 clinical trials: NCT00542984, NCT00543023, and NCT00543218. These trials were completed and enrolled a total of 237 postmenopausal women with osteoporosis in South Korea, China, and Taiwan. All trials were active-controlled and randomized.
Teriparatide 20 micrograms/day is a specific dosage form of teriparatide, a drug used to treat osteoporosis. The 20 micrograms per day dose is the standard dose for postmenopausal women with osteoporosis. It is being developed by Eli Lilly and Company and is currently in Phase 3 clinical trials.